Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574196 | 0.86 | GAA (0.58) | GAACD44KDM1AKDM1BALDH1A1 | |
| SCHEMBL205430 | 0.86 | GAA (0.58) | GAACD44KDM1AKDM1BALDH1A1 | |
| SCHEMBL29659108 | 0.86 | GAA (0.50) | GAACD44KDM1AKDM1BALDH1A1 | |
| SCHEMBL1397082 | 0.86 | KDM1A (0.43) | GAACD44KDM1AKDM1BALDH1A1 | |
| SCHEMBL8492289 | 0.86 | GAA (0.50) | GAACD44KDM1AKDM1BALDH1A1 | |
| SCHEMBL29939627 | 0.86 | KDM1A (0.43) | GAACD44KDM1AKDM1BALDH1A1 | |
| SCHEMBL12478277 | 0.86 | GAA (0.67) | GAACD44KDM1AKDM1BALDH1A1 | |
| SCHEMBL14475236 | 0.81 | GAA (0.46) | GAACD44KDM1AKDM1BALDH1A1 | |
| SCHEMBL24716192 | 0.79 | ALDH1A1 (0.47) | GAACD44KDM1AKDM1BALDH1A1 | |
| SCHEMBL10144165 | 0.79 | CD44 (0.52) | GAACD44KDM1AKDM1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115583978-A | Phenazine ruthenium (II) complex hexafluorophosphate for inhibiting cryptococcus as well as preparation method and application thereof | 西南大学 | 2023-01-10 | — | — | CN | claimed |
| US-11211562-B2 | Method of synthesis for organic semiconducting polymers | PHILLIPS 66 COMPANY (US) | 2021-12-28 | — | — | US | claimed |
| US-20210061945-A1 | PROCESS FOR PREPARING ORGANIC SEMICONDUCTING POLYMERS | PHILLIPS 66 COMPANY (US) | 2021-03-04 | — | — | US | claimed |
| US-20210066609-A1 | METHOD OF SYNTHESIS FOR ORGANIC SEMICONDUCTING POLYMERS | PHILLIPS 66 COMPANY (US) | 2021-03-04 | — | — | US | claimed |
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-12479807-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4630412-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2025-10-15 | — | — | EP | disclosed |
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| CN-113166117-B | Heteroaromatic compounds as VANIN inhibitors | 勃林格殷格翰国际公司 | 2025-04-15 | — | — | CN | disclosed |
| US-12101992-B2 | Organic semiconducting compounds | Raynergy Tek Incorporation (TW) | 2024-09-24 | — | — | US | disclosed |
| WO-2024121130-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121130-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| EP-0556334-A4 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | UNIV MICHIGAN (US) | 1995-03-29 | — | — | EP | disclosed |
| US-5360795-A | Treating cytomegalo virus and herpes simplex viruses | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-11-01 | — | — | US | disclosed |
| WO-1994008456-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0556334-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1993-08-25 | — | — | EP | disclosed |
| WO-1992007867-A1 | POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1992-05-14 | — | — | WO | disclosed |
| EP-0456609-A1 | Fluorescent yellow 1,2,3,4-tetrachloro-11H-isoindolo-[2,1-a]-benzimidazol-11-one pigments | CIBA-GEIGY AG (CH) | 1991-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358910-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | GAA 105/4885CD44 3382/4885KDM1A 3373/4885 |
| US-12479807-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | GAA 181/4885CD44 1849/4885KDM1A 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.